We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Pnt4.0

Pantethine Research

Mostly mechanism / observational

9 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Pantethine studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality randomised trials published 1982–2026.

Based on 9 studies · 4 RCTs

Confidence

Moderate confidence

By outcome

Cholesterol & lipidsModest LDL/triglyceride reduction and HDL increase (older/small human data) · 8-16 weeks
Mostly mechanism / observational3 studies
Glucose & metabolicCoA-pathway lipid metabolism support · 8-16 weeks
Mostly mechanism / observational3 studies

Steady research

2 studies in the last 5 years

198220042026

1RCT2011

Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M · Nutr Res (2011)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

2RCT2015

Chen YQ, Zhao SP, Zhao YH · J Clin Lipidol (2015)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

3RCT1987

Prisco D, Rogasi PG, Matucci M, Paniccia R, Abbate R, Gensini GF · Angiology (1987)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source

4RCT2014

Evans M, Rumberger JA, Azumano I, Napolitano JJ, Citrolo D, Kamiya T · Vasc Health Risk Manag (2014)

No plain-language summary recorded for this citation — open the paper to read its abstract.

View source Free full text

5Review2026

In plain English: Understanding CoA as a regulator of metabolic adaptability provides a unifying framework for interpreting both shared mechanisms and disease divergence.

Di Meo I, Anikster Y, Tiranti V, Iuso A. · Journal of inherited metabolic disease (2026)

Instead, impaired compartment-specific CoA handling and failure to sustain CoA-dependent flux under increased metabolic demand are emerging as central pathogenic concepts.
Perturbation of fatty acid handling, acyl-CoA/acylcarnitine balance, mitochondrial function, iron homeostasis, protein acylation and 4'-phosphopantetheinylation may contribute to tissue-selective vulnerability.
Therapeutic strategies are therefore likely to require disease-specific approaches, including precursor bypass or PANK activation where pathway flux can be restored, early pantethine supplementation in cardiomyopathic forms, and downstream or gene-directed strategies for COASY-related disorders.

View source

6In Vitro1982

In plain English: An in-vitro study found pantethine reduced cholesterol biosynthesis in cultured human skin fibroblasts.

Ranganathan S et al. · Atherosclerosis (1982)

Reduced cholesterol biosynthesis in cultured (human-derived) skin fibroblasts
In-vitro cell-culture study — NOT a human clinical trial
Active metabolite of vitamin B5 (pantothenic acid)

View source

7Animal2023

In plain English: An animal study found pantethine ameliorated recognition impairment in a disease model.

Chen J et al. · Mol Nutr Food Res (2023)

Improved recognition memory in a mouse model
Preclinical (not human)
Exploratory neurological signal

View source

8In Vitro1987

In plain English: A study found pantethine inhibits cholesterol and fatty-acid synthesis.

Cighetti G et al. · J Lipid Res (1987)

Inhibited cholesterol and fatty-acid synthesis
CoA/lipid-metabolism pathway

9In Vitro2015

In plain English: A study found pantethine altered lipid composition and cholesterol content in cells.

van Gijsel-Bonnello M et al. · J Cell Physiol (2015)

Altered lipid composition and lowered cellular cholesterol
Cell-based mechanistic study
Supports lipid-modulating action

View source

View in Research Library

Pantethine Research

Mostly mechanism / observational

Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation.

Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study.

Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia.

Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation.

From Common Pathway to Divergent Diseases: Metabolic Aspects of Inborn Errors of CoA Biosynthesis

Effect of pantethine on the biosynthesis of cholesterol in human skin fibroblasts.

Pantethine Ameliorates Recognition Impairment in a Mouse Model of Alzheimer's Disease by Modulating Cholesterol Content and Intestinal Flora Species.

Pantethine inhibits cholesterol and fatty acid syntheses and stimulates carbon dioxide formation in isolated rat hepatocytes.

Pantethine Alters Lipid Composition and Cholesterol Content of Membrane Rafts, With Down-Regulation of CXCL12-Induced T Cell Migration.